Speech-Language Pathologists in Mitchellville, MD Accepting Medicare

2 Speech-Language Pathologists found. Showing 1 - 2

Mr. John Calvin Alberty Jr., MS CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9912 Glenkirk Way, Mitchellville, MD 20721 Phone: 301-325-7560    Fax: 301-576-8550

Anna K Nowaczyk, SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 10450 Lottsford Rd, Mitchellville, MD 20721 Phone: 301-541-5017    Fax: 214-305-3399

News Archive

Researcher is exploring safer and more effective treatment for leukemia

A potentially safer, more effective chemotherapy treatment for patients with blood-related cancers, such as leukemia, who need a particular bone marrow transplant procedure is under study at the University of Arizona Health Sciences.

Study could open door for new treatment targets to help Parkinson's disease patients walk more easily

Two secrets of one of the brain's most enigmatic regions have finally been revealed. In a pair of new studies, scientists from the Gladstone Institutes have discovered a specific neural circuit that controls walking, and they found that input to this circuit is disrupted in Parkinson's disease.

Unique form of chronic sinusitis found in older patients

Older patients with a diagnosis of chronic sinusitis - a disease of the nasal cavity and paranasal sinuses that often persists over many years - have a unique inflammatory signature that may render them less responsive to steroid treatment, according to a new study published by Vanderbilt researchers.

Tongjitang Chinese Medicines' net revenue rises 31.5% in fourth quarter 2009

Tongjitang Chinese Medicines Company, a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced its financial results for the fourth quarter of 2009 and for the full year ended December 31, 2009.

GSK re-submits sNDA for Avodart to FDA

GlaxoSmithKline announced today that it has re-submitted the supplemental New Drug Application for Avodart® (dutasteride) for prostate cancer risk reduction among men at increased risk of developing the disease to the US Food and Drug Administration.

Read more Medical News

› Verified 2 days ago